Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KITE-Dep
2018-003421-28Phase 2Terminated
- Sponsor
- St Patrick's Mental Health Services
- Start
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in major depressive episode (MDE) and major depressive disorder (MDD) comparing Ketamine + ECT with Midazolam + ECT (2 arms). Primary endpoint: Difference in MADRS scores between ketamine and midazolam groups. Started Sep 2018; status: terminated.
02
Drugs
ketaminemidazolam
03
Conditions
major depressive episode (MDE)major depressive disorder (MDD)
Beyond the preview
Go deeper on 2018-003421-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003421-28.